A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

NCT04041011 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316
DRUG: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316
DRUG: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

Sponsor

Jiangsu HengRui Medicine Co., Ltd.